aMoon Fund

Lutris Pharma is an Israel-based biopharmaceutical company focused on improving anti-cancer therapy. It develops drugs to enhance treatment effectiveness, including a proprietary topical B-Raf inhibitor LUT014 that enables administration of epidermal growth factor receptor inhibitors without the cutaneous side effects that typically interrupt therapy. Founded in 2015 and based in Tel Aviv-Yafo, Lutris Pharma aims to improve treatment continuity and patient quality of life for those treated with EGFR inhibitors.

Air Doctor Ltd. operates an online marketplace that connects travelers with verified healthcare professionals in various locations. Founded in 2016 and based in Motza Illit, Israel, the platform allows users to search for and schedule appointments with doctors, dentists, emergency clinics, pharmacies, and other healthcare specialists. By providing access to practitioner profiles and patient reviews, Air Doctor simplifies the process of obtaining medical care abroad, ensuring that users can find professionals who speak their language and meet their specific needs. This service aims to enhance the experience of travelers by making healthcare access straightforward and efficient in unfamiliar destinations.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Founded in 2017, Nectin Therapeutics develops novel monoclonal antibodies targeting the Nectin family of receptors and ligands. These antibodies aim to treat solid and hematological malignancies by modulating immune checkpoint mechanisms.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Founded in 2017, Nectin Therapeutics develops novel monoclonal antibodies targeting the Nectin family of receptors and ligands. These antibodies aim to treat solid and hematological malignancies by modulating immune checkpoint mechanisms.

Founded in 2017, Curesponse is a diagnostics company based in Tel Aviv-Yafo, Israel. It develops a three-dimensional tissue culture system for modelling cancer growth and drug response, preserving the cancer's original microenvironment. The company offers an online platform enabling patients and clinicians to send tumor samples for testing, aiming to improve personalized cancer treatment by matching the most effective drugs to individual patients' tumors.

Igentify Ltd is an Israeli company specializing in preventive healthcare through genomic products and services. Founded in 2016 by Galit Delmar and Yagil Tzur, Igentify is headquartered in Haifa. The company focuses on enhancing access to genomic information for clinicians, laboratories, and patients through its end-to-end digital genetic platform. One of its key offerings is FamilyFirst, an expanded carrier screening designed specifically for the Jewish and Israeli populations. Igentify's platform addresses the increasing demand for genomic medicine by digitizing various processes related to genetic testing, including patient education, consent collection, data analysis, and the delivery of personalized results. This approach aims to streamline and simplify the complexities often associated with genomic healthcare.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing small-molecule therapeutics for patients with rare and aggressive cancers, using a bioinformatics platform and next-generation sequencing to identify tumorigenic drivers and guide targeted therapies. The company is developing AL101, an intravenous gamma secretase inhibitor for Notch-activating tumors such as adenoid cystic carcinoma, which is in Phase II, and AL102, an oral gamma secretase inhibitor for desmoid tumors, in Phase I. Ayala has a collaboration with Novartis to advance AL102 for multiple myeloma. Founded in 2017, the company is headquartered in Rehovot, Israel.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing artificial intelligence-based systems for cancer diagnosis. Its flagship product, the Ibex Second Read system, operates alongside human pathologists, analyzing cases in parallel to identify discrepancies between the pathologist's diagnoses and its own analysis. By leveraging advancements in AI, data science, image analysis, and machine learning, Ibex aims to enhance clinical decision-making and streamline pathology laboratory workflows. The technology utilizes digitized glass slides and electronic medical records to uncover underlying patterns and extract clinical insights, ultimately enabling pathologists to provide rapid, objective, and accurate diagnoses. Through its innovative approach, Ibex strives to improve patient outcomes and quality of life in the field of cancer care.

Nobio Ltd. is a biotechnology company based in Petah Tikva, Israel, specializing in the development of innovative nano-polymer additives that provide protection against microbial infections. Its technology enables the transformation of both implantable and non-implantable devices into biofilm-resistant platforms. Nobio's product offerings include a universal bonding agent designed for strong adhesion to various dental surfaces and restorative materials, as well as flowable composites suitable for dental restorations and sealants. The core of Nobio's technology consists of potent particles embedded with highly-active antimicrobial structures that kill bacteria upon contact, effectively preventing medical device contamination indefinitely. This unique approach positions Nobio as a leader in the creation of durable antimicrobial materials and surfaces, enhancing safety and efficacy in medical and dental applications.

Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.

CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.